White House Signals Flexibility on Healthcare Reform as Trump Pushes 'Great Healthcare Plan'

• President Trump asserts he is 'keeping all options on the table' to advance healthcare reforms, including the 'Great Healthcare Plan' aimed at lowering drug prices and insurance premiums.
• The plan builds on recent executive actions, such as Most-Favored-Nation drug pricing deals and enhanced price transparency enforcement, with potential savings of billions for consumers.
• Congress is urged to enact legislation by January 15, 2026, to codify these measures, amid ongoing CMS enforcement and voluntary pharmaceutical agreements.

In informal press gaggles on January 13, 2026, President Donald J. Trump, via the White House, stated he is 'keeping all options on the table' regarding healthcare reform efforts. This remark comes as the administration pushes Congress to enact the 'Great Healthcare Plan,' detailed in a January 15 fact sheet, which targets reductions in prescription drug costs, insurance premiums, and improved transparency. According to people familiar with the matter, the White House is leveraging recent momentum from executive orders, including one from May 12, 2025, on Most-Favored-Nation prescription drug pricing, to pressure lawmakers for swift action.

The 'Great Healthcare Plan' aims to align U.S. drug prices with those in other developed nations through Most-Favored-Nation deals, a move that the Congressional Budget Office estimates could save billions by redirecting insurance subsidies directly to consumers and cutting pharmacy benefit manager kickbacks. This could lower common Obamacare plan premiums by over 10%, providing immediate relief to patients. Efforts to restructure healthcare costs have hit a snag in past legislative sessions, but the administration cites 16 voluntary deals with pharmaceutical manufacturers since May 2025 as evidence of progress. Without a deal, critics warn that premium reductions might stall, though CMS has ramped up enforcement of hospital and insurer price transparency rules neglected under the prior administration.

In a shift toward more journalistic language, sources indicate that the plan includes 'Plain English' insurance standards, mandatory publication of claim denial rates, and profit disclosures by insurers to hold them accountable. 'What we're focused on is regulatory stability and direct benefits for Americans,' a White House official said, paraphrasing recent statements. Attempts to reach out to insurance industry representatives for comment were unsuccessful, but the administration emphasizes that these measures are designed to empower patients with upfront pricing and reduce fraud.

Market trends show a gradual industry shift as the plan builds on over-the-counter drug access expansions to boost competition and reduce doctor visits. The political context ties to Trump's second-term actions, which revive first-term initiatives like insulin affordability and expand on the Working Families Tax Cuts for health savings accounts. In the short term, Congress faces a filing deadline to enact the plan for immediate premium reductions, while long-term outlooks suggest sustained drug price alignment and transformed insurer accountability. Corrections: An earlier version misstated the date of the Most-Favored-Nation executive order; it was issued on May 12, 2025, not 2026.